Achaogen, Inc.
Achaogen to Host Conference Call and Webcast of Third Quarter 2017 Financial Results on November 8, 2017
30 oct. 2017 16h01 HE | Achaogen, Inc.
SOUTH SAN FRANCISCO, Calif., Oct. 30, 2017 (GLOBE NEWSWIRE) -- Achaogen, Inc. (NASDAQ:AKAO), a late-stage biopharmaceutical company discovering and developing innovative antibacterials addressing...
Achaogen, Inc.
Achaogen Announces New Employment Inducement Grants
27 oct. 2017 08h01 HE | Achaogen, Inc.
SOUTH SAN FRANCISCO, Calif., Oct. 27, 2017 (GLOBE NEWSWIRE) -- Achaogen, Inc. (NASDAQ:AKAO), a late-stage biopharmaceutical company developing innovative antibacterials addressing multi-drug...
Achaogen, Inc.
Achaogen Submits Plazomicin New Drug Application (NDA) to the U.S. FDA for Treatment of Complicated Urinary Tract Infections and Bloodstream Infections
26 oct. 2017 08h01 HE | Achaogen, Inc.
-- Investigational drug has potential to treat certain MDR gram-negative pathogens, including carbapenem-resistant Enterobacteriaceae (CRE) -- SOUTH SAN FRANCISCO, Calif., Oct. 26, 2017 (GLOBE...
Achaogen, Inc.
Achaogen IDWeek 2017 Presentations Feature Plazomicin’s Unique Potential to Treat MDR Enterobacteriaceae
05 oct. 2017 08h01 HE | Achaogen Inc.
-- Presentations emphasize potential role for plazomicin in treating bloodstream infections (BSI) due to carbapenem-resistant Enterobacteriaceae (CRE) as well as potential long-term clinical benefits...
Achaogen, Inc.
Achaogen Awarded up to $18 Million Contract by BARDA to Support Development of Orally-Administered Antibacterial Candidate C-Scape
28 sept. 2017 08h01 HE | Achaogen Inc.
Non-dilutive funding to support clinical development of antibacterial candidate for ESBL infections Company expects top-line Phase 1 results in 2017 and initiation of pivotal Phase 3 trial in 2018 ...
Achaogen, Inc.
Achaogen Announces Multiple Plazomicin Presentations at IDWeek 2017
27 sept. 2017 08h01 HE | Achaogen Inc.
SOUTH SAN FRANCISCO, Calif., Sept. 27, 2017 (GLOBE NEWSWIRE) -- Achaogen, Inc. (NASDAQ:AKAO), a late-stage biopharmaceutical company developing innovative antibacterials addressing...
Achaogen, Inc.
Achaogen Announces New Employment Inducement Grants
26 sept. 2017 04h01 HE | Achaogen Inc.
SOUTH SAN FRANCISCO, Calif., Sept. 26, 2017 (GLOBE NEWSWIRE) -- Achaogen, Inc. (NASDAQ:AKAO), a late-stage biopharmaceutical company developing innovative antibacterials addressing multi-drug...
Achaogen, Inc.
Achaogen to Present at the 2017 Cantor Fitzgerald Global Healthcare Conference
18 sept. 2017 16h01 HE | Achaogen Inc.
SOUTH SAN FRANCISCO, Calif., Sept. 18, 2017 (GLOBE NEWSWIRE) -- Achaogen, Inc. (NASDAQ:AKAO), a late-stage biopharmaceutical company developing innovative antibacterials addressing multi-drug...
Achaogen, Inc.
Achaogen Adds Liz Bhatt as Chief Business Officer
18 sept. 2017 08h01 HE | Achaogen Inc.
SOUTH SAN FRANCISCO, Calif., Sept. 18, 2017 (GLOBE NEWSWIRE) -- Achaogen, Inc. (NASDAQ:AKAO), a late-stage biopharmaceutical company developing innovative antibacterials addressing multi-drug...
Achaogen, Inc.
Achaogen Announces New Employment Inducement Grants
21 août 2017 16h01 HE | Achaogen Inc.
SOUTH SAN FRANCISCO, Calif., Aug. 21, 2017 (GLOBE NEWSWIRE) -- Achaogen, Inc. (NASDAQ:AKAO), a late-stage biopharmaceutical company developing innovative antibacterials addressing multi-drug...